TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36946298
Drug: Oxycodone treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone treatment, dosage and duration not available
Study: 36946505
Drug: Booster vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccination (BV) using inactivated virus vaccines (the third dose)
Study: 36947042
Drug: Topical lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical lovastatin 2% plus cholesterol 2% cream (lovastatin-cholesterol); applied once or twice daily for 12 weeks
Study: 36947042
Drug: Topical lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical lovastatin 2% cream (lovastatin); applied once or twice daily for 12 weeks
Study: 36947593
Drug: ASO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASO therapy targeting an evolutionarily conserved region at the start of the UBE3A gene
Study: 36947713
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Leucine (MET+LEU) treatment
Study: 36947734
Drug: Naporafenib 200
Normalized name: Naporafenib
DrugBank: Naporafenib (DB18865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naporafenib 200 mg twice a day plus trametinib 1 mg once daily
Study: 36947734
Drug: Naporafenib 400
Normalized name: Naporafenib
DrugBank: Naporafenib (DB18865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily
Study: 36948246
Drug: D-1553 (garsorasib)
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-1553 (garsorasib) 600 mg twice a day
Study: 36948246
Drug: D-1553 (garsorasib)
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-1553 (garsorasib) at recommended phase 2 dose
Study: 36948372
Drug: NOV03 (perfluorohexyloctane)
Normalized name: NOV03
DrugBank: Perfluorohexyloctane (DB17823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOV03 (perfluorohexyloctane) ophthalmic drop, 4 times daily for 8 weeks
Study: 36948372
Drug: Hypotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic saline (0.6%), 4 times daily for 8 weeks
Study: 36948424
Drug: Sequential HSgFOBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential HSgFOBT
Study: 36948504
Drug: Nivolumab/ipilimumab salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab/ipilimumab salvage therapy
Study: 36948505
Drug: PrCa VBIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrCa VBIR (adenovirus vector and plasmid DNA expressing PSMA, PSA, PSCA) plus tremelimumab 80 mg and sasanlimab 300 mg (RP2D) in mCRPC
Study: 36948505
Drug: PrCa VBIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrCa VBIR plus tremelimumab 80 mg (Cohort 1B-BCR) in BCR
Study: 36948505
Drug: PrCa VBIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrCa VBIR plus tremelimumab 80 mg plus sasanlimab 130 mg (Cohort 5B-BCR) in BCR
Study: 36948567
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy components (mindful attention, decentring, values and committed action)
Study: 36948568
Drug: Intravenous Ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Ferric Carboxymaltose (10 mL, 50 mg Fe)
Study: 36949155
Drug: Asciminib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asciminib monotherapy 10-200 mg once or twice daily
Study: 36949248
Drug: Ulotaront 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulotaront 150 mg
Study: 36949478
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT) + thoracic endovascular aortic repair (TEVAR)
Study: 36949579
Drug: Dyad combinations
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyad combinations (three different gels)
Study: 36949846
Drug: Movement Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement Group (twice-weekly group improvisational dance classes for 12 weeks)
Study: 36949953
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of CoronaVac
Study: 36950217
Drug: Everolimus 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 4.5 mg/m² orally
Study: 36950415
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a dose of 1.5 mg/kg
Study: 36950415
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a dose of 1.5 mg/kg in Group N
Study: 36950415
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a dose of 1.5 mg/kg in Group OW
Study: 36950415
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a dose of 1.5 mg/kg in Group O
Study: 36950450
Drug: Lomecel-B (intramyocardial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomecel-B (intramyocardial injections)
Study: 36950929
Drug: Lasmiditan (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan (initial dose 100 mg, adjustable to 50 mg or 200 mg)
Study: 36951196
Drug: MF59-adjuvanted trivalent
Normalized name: Influenza, adjuvanted, trivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted trivalent inactivated influenza vaccine (aTIV)
Study: 36951196
Drug: Nonadjuvanted vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted vaccine (TIV)
Study: 36951827
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg 3 times weekly
Study: 36951827
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg once weekly
Study: 36951827
Drug: Progesterone receptor
Normalized name: Progesterone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone receptor
Study: 36951827
Drug: Sex hormone-binding
Normalized name: Testosterone bound to sex hormone-binding globulin (SHBG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone-binding globulin and high-density lipoprotein cholesterol
Study: 36952010
Drug: Cognitive games
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive games integrated in the dreaMS app, played twice a week for 5 weeks
Study: 36952231
Drug: Avelumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (10 mg/kg intravenously every 2 weeks) + Cabozantinib (20 mg/day)
Study: 36952231
Drug: Avelumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (10 mg/kg intravenously every 2 weeks) + Cabozantinib (40 mg/day)
Study: 36952231
Drug: Avelumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (10 mg/kg intravenously every 2 weeks) + Cabozantinib (60 mg/day)
Study: 36952517
Drug: SMART (Self-Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART (Self-Management for Amputee Rehabilitation using Technology) with weekly support sessions from a trained peer mentor for goal setting and action planning for six weeks.
Study: 36952517
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with weekly social contacts for six weeks.
Study: 36958363
Drug: Low calorie
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calorie and protein targets (6 kcal/kg per day and 0.2-0.4 g/kg per day protein)
Study: 36958363
Drug: Standard calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard calorie and protein targets (25 kcal/kg per day and 1.0-1.3 g/kg per day protein)
Study: 36958470
Drug: Dupilumab 100
Normalized name: DUPILUMAB 100MG/0.67ML INJ,SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 100 mg every 2 weeks
Study: 36958473
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy algorithm incorporating the respiratory exchange ratio
Study: 36958479
Drug: Radiofrequency Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency Induced Thermal Therapy (RFITT)
Study: 36958796
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg every 4 months through month 20)
Study: 36958796
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg/kg/day, tapered after month 24)
Study: 36958940
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma ferritin (˃55.7 ng/mL) and high triglyceride (˃1.9 mmoL/L)
Study: 36958977
Drug: Self-administered stretching
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered stretching exercises
Study: 36958998
Drug: d-serine 80
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-serine 80 mg/kg
Study: 36958998
Drug: d-serine 100
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-serine 100 mg/kg
Study: 36958998
Drug: d-serine 120
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-serine 120 mg/kg
Study: 36959540
Drug: 7 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 weeks external beam radiotherapy (EBRT) and 3 years androgen deprivation therapy (ADT) with one concurrent cycle of systemic treatment (three, six, or nine GBq)
Study: 36959634
Drug: Iron group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron group (micronutrient powder with 12.5 mg of iron daily)
Study: 36959672
Drug: Autologous leukocyte-
Normalized name: interferon alfa-3n,human leukocyte derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous leukocyte- and platelet-rich fibrin (L-PRF)
Study: 36959672
Drug: L-PRF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF and commercially available fibrin sealants
Study: 36959874
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable antipsychotics (LAIs)
Study: 36959874
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from LAIs to oral antipsychotic medications
Study: 36959874
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from shorter to longer injection interval LAIs
Study: 36959966
Drug: Matched daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched daily samples of urine E3G and serum E2
Study: 36960538
Drug: Vonoprazan (VPZ)
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan (VPZ) 20 mg
Study: 36960538
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitors (PPI) - Lansoprazole 30 mg or Esomeprazole 20 mg
Study: 36960716
Drug: Pocket wash
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pocket wash (500 mL antibiotic solution) and postoperative antibiotics for 3 days along with standard prophylactic measures (chlorhexidine skin preparation, intravenous antibiotics, and TYRX-a antibiotic envelope)
Study: 36960716
Drug: Standard prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylactic measures (chlorhexidine skin preparation, intravenous antibiotics, and TYRX-a antibiotic envelope)
Study: 36960779
Drug: Intraoperative enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative enteral nutrition feeding (100 kcal/100 mL at 10-20 mL/h)
Study: 36961220
Drug: Core decompression
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Core decompression with autologous osteoblastic cell transplantation (5 mL with 20 x 10^6 cells/mL)
Study: 36961220
Drug: Core decompression
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Core decompression with placebo (5 mL of solution without cells)
Study: 36961591
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (NSPT) with patients having major stress levels
Study: 36961591
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (NSPT) with patients having avoidance coping strategies
Study: 36961650
Drug: Ari 2MRTU
Normalized name: OVIS ARIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ari 2MRTU 960 (960 mg) every 56 ± 2 days (four injections scheduled)
Study: 36961650
Drug: AOM 400
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AOM 400 (400 mg) every 28 ± 2 days (eight injections scheduled)
Study: 36962514
Drug: SATC (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SATC (treatment as usual)
Study: 36962706
Drug: Rectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rectal artesunate (RAS) pre-referral treatment
Study: 36962706
Drug: Community Access
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Access to Rectal Artesunate for Malaria (CARAMAL) project
Study: 36962786
Drug: Monthly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly follow-up
Study: 36962786
Drug: Standard-of-care (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (weekly follow-up)
Study: 36962838
Drug: 20μg/20μg (fractional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20μg/20μg (fractional dose) of BNT162b2
Study: 36962838
Drug: 30μg/30μg (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30μg/30μg (full dose) of BNT162b2
Study: 36962838
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of reduced dose to full dose
Study: 36962857
Drug: Reactive focal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive focal drug administration (RFDA)
Study: 36962953
Drug: Baseline seroprevalence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline seroprevalence of IgG antibodies to SARS-CoV-2
Study: 36963116
Drug: Deep learning
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep learning enabled MV-based real-time image guided radiation therapy
Study: 36963417
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group (digital data informed treatment adjustments)
Study: 36963417
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pharmacy refill rates informed treatment adjustments)
Study: 36963515
Drug: Caring Contacts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caring Contacts with introductory phone call (CC+)
Study: 36963515
Drug: Caring Contacts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caring Contacts without introductory phone call (CC)
Study: 36963815
Drug: Three additional
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three additional 40 µg doses administered at monthly intervals (experimental arm)
Study: 36963815
Drug: Single 40 µg
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single 40 µg booster vaccination at month 6 (classical arm)
Study: 36963852
Drug: Premeal load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premeal load of almonds (20 g) 30 minutes before major meals
Study: 36964084
Drug: Presatovir 200
Normalized name: Presatovir
DrugBank: Presatovir (DB12165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presatovir 200 mg on day 1 and 100 mg daily on days 2 to 14
Study: 36964422
Drug: CBT-TS (brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-TS (brief CBT for Treatment Seeking) delivered by phone
Study: 36964529
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) with a dose of 15-24 Gy in 1 or 3 fractions
Study: 36964590
Drug: Postoperative vasopressor
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative vasopressor infusions (PVI)
Study: 36964593
Drug: Behavioral medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral medicine intervention in physical therapy (BMIP) plus routine exercise-based cardiac rehabilitation (exCR)
Study: 36964872
Drug: CMAB008 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMAB008 3 mg/kg
Study: 36964872
Drug: Innovator infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Innovator infliximab 3 mg/kg
Study: 36964977
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (IR) defined as an estimated glucose disposal rate (eGDR) ≤9.0 mg/kg/min
Study: 36966310
Drug: Intra-articular corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular corticosteroid injections (IACSI)
Study: 36966349
Drug: Adjuvant melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant melatonin 20 mg (4 tablets of 5 mg) at 10 pm for 5 years
Study: 36966799
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg once per day for 8 weeks plus standard tuberculosis therapy
Study: 36966799
Drug: Standard tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard tuberculosis therapy alone (control group)
Study: 36966799
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg once per day
Study: 36966905
Drug: Third monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third monovalent mRNA vaccines
Study: 36967244
Drug: Teclistamab (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab (1.5 mg/kg weekly)
Study: 36967244
Drug: Physician's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's Choice (PC) of therapy
Study: 36967281
Drug: Occupational exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational exposure to quaternary ammonium compounds
Study: 36967527
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of glucose-lowering drugs (specific drugs not mentioned)
Study: 36967527
Drug: Metformin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (in clinical pharmacokinetic trial, n=10)
Study: 36968554
Drug: 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir (30/15/40/10 mg) fixed-dose combination of granules in a capsule
Study: 36968652
Drug: Mid-dose PHEN/TPM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-dose PHEN/TPM (7.5 mg/46 mg)
Study: 36968652
Drug: Top-dose PHEN/TPM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top-dose PHEN/TPM (15 mg/92 mg)
Study: 36968754
Drug: Step guided
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step guided multicomponent interprofessional intervention program (group therapy, daily training, individual sessions)
Study: 36969023
Drug: Moderately hypo-fractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately hypo-fractionated radiotherapy (60Gy in 24 fractions) concurrent with S-1
Study: 36969063
Drug: TDM-guided dosing
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDM-guided dosing of alectinib (intervention arm A)
Study: 36969063
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing of alectinib 600 mg taken twice daily with food (control arm B)
Study: 36969244
Drug: Inactivated JEV
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated JEV vaccine followed by YF17D challenge
Study: 36969390
Drug: Smartphone cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone cognitive behavioral therapy (CBT) for body dysmorphic disorder, specific dosage and duration not mentioned.
Study: 36969546
Drug: Treatment (manualized,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (manualized, family-tailored education and problem-solving adherence intervention)
Study: 36969747
Drug: ctDNA monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ctDNA monitoring during first-line treatment
Study: 36969889
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg TMF
Study: 36969982
Drug: Mobile interventions
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile interventions plus nicotine replacement therapy sampling (NRT-S)
Study: 36970054
Drug: Gemcitabine/Nab-Paclitaxel/Xeloda (GAX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/Nab-Paclitaxel/Xeloda (GAX) in Combination With Cisplatin and Irinotecan (GAX-CI)
Study: 36970056
Drug: TAK-931 50
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-931 50 mg once daily for 14 days in 21-day cycles (schedule A)
Study: 36970056
Drug: TAK-931 50
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-931 50 mg once daily days 1-14 in 21-day cycles
Study: 36970275
Drug: Subcutaneous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ketamine infusion
Study: 36970545
Drug: 10-week O-RAGT
Normalized name: 10-O-demethylcolchicine
DrugBank: Colchiceine (DB15534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-week O-RAGT program in combination with usual care physiotherapy
Study: 36970876
Drug: Vevorisertib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vevorisertib monotherapy
Study: 36970971
Drug: Sintilimab 200
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200 mg plus Pegaspargase 2500 U/m, combined with Anlotinib and radiotherapy
Study: 36971560
Drug: Lumacaftor-ivacaftor treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor-ivacaftor treatment
Study: 36971771
Drug: Secukinumab low
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab low dose (LD [75/150 mg])
Study: 36971771
Drug: Secukinumab high
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab high dose (HD [75/150/300 mg])